Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS
Autor: | Carme Pedro, Heinz Sill, Michael Lübbert, Mario Cazzola, A.A. van de Loosdrecht, Heinz Tuechler, Javier Grau, Hartmut Döhner, Michael Pfeilstöcker, Alan F. List, A.A.N. Giagounidis, Peter L. Greenberg, M.G. Della Porta, Francesc Cobo, F. Solé, Gail J. Roboz, Guillermo Sanz, Sabine Blum, M. Martinez-de-Sola, Barbara Hildebrandt, Ulrich Germing, Detlef Haase, Amy E. DeZern, Rainer Haas, David P. Steensma, Richard F. Schlenk, M. Nomdedeu, Dolors Costa, María Díez-Campelo, Mikkael A. Sekeres, Christina Ganster, Rami S. Komrokji, Itziar Oiartzabal, Benet Nomdedeu, Reinhard Stauder, Arturo Pereira, Jordi Esteve, Sigrid Machherndl-Spandl, Maria Teresa Voso, Xavier Calvo, Maria-Teresa Cedena, Tobias Schroeder, Uwe Platzbecker, G. Garcia-Manero, Peter Valent, M. López-Pavía, Brayan Merchan, Blanca Xicoy, Andrea Kuendgen, Claudia D. Baldus |
---|---|
Přispěvatelé: | Hematology, CCA - Imaging and biomarkers |
Rok vydání: | 2020 |
Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty MEDLINE Displàsia Risk Assessment Article Sub classification Text mining Internal medicine hemic and lymphatic diseases Diagnosis Biomarkers Tumor medicine Humans Aged Aged 80 and over Biomarkers Tumor/analysis Female Follow-Up Studies Middle Aged Myelodysplastic Syndromes/classification Myelodysplastic Syndromes/diagnosis Myelodysplastic Syndromes/therapy Neoplasms Second Primary/classification Neoplasms Second Primary/diagnosis Neoplasms Second Primary/therapy Prognosis Retrospective Studies Risk Assessment/methods Survival Rate Survival rate Therapy related business.industry Myelodysplastic syndromes Myeloid leukemia Neoplasms Second Primary Retrospective cohort study Hematology Settore MED/15 medicine.disease Classificació Risk factors Myelodysplastic Syndromes business Síndromes mielodisplàsiques |
Zdroj: | Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona Leukemia r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname Kuendgen, A, Nomdedeu, M, Tuechler, H, Garcia-Manero, G, Komrokji, R S, Sekeres, M A, Della Porta, M G, Cazzola, M, DeZern, A E, Roboz, G J, Steensma, D P, Van de Loosdrecht, A A, Schlenk, R F, Grau, J, Calvo, X, Blum, S, Pereira, A, Valent, P, Costa, D, Giagounidis, A, Xicoy, B, Döhner, H, Platzbecker, U, Pedro, C, Lübbert, M, Oiartzabal, I, Díez-Campelo, M, Cedena, M T, Machherndl-Spandl, S, López-Pavía, M, Baldus, C D, Martinez-de-Sola, M, Stauder, R, Merchan, B, List, A, Ganster, C, Schroeder, T, Voso, M T, Pfeilstöcker, M, Sill, H, Hildebrandt, B, Esteve, J, Nomdedeu, B, Cobo, F, Haas, R, Sole, F, Germing, U, Greenberg, P L, Haase, D & Sanz, G 2021, ' Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS ', Leukemia, vol. 35, no. 3, pp. 835-849 . https://doi.org/10.1038/s41375-020-0917-7 r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe Leukemia, 35(3), 835-849. Nature Publishing Group Leukemia, vol. 35, no. 3, pp. 835-849 |
ISSN: | 0887-6924 |
Popis: | In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are categorized together with therapy-related acute myeloid leukemia (AML) and t-myelodysplastic/myeloproliferative neoplasms into one subgroup independent of morphologic or prognostic features. Analyzing data of 2087 t-MDS patients from different international MDS groups to evaluate classification and prognostication tools we found that applying the WHO classification for p-MDS successfully predicts time to transformation and survival (both p |
Databáze: | OpenAIRE |
Externí odkaz: |